Secondary non-response due to antibody formation in a child after three injections of botulinum toxin B into the salivary glands

Developmental Medicine and Child Neurology

Volumn 49, Issue 1, 2007, Pages 62-64

  Berweck, Steffen ^a   Schroeder, A Sebastian ^a   Lee, Seung Hee ^a   Bigalke, Hans ^b   Heinen, Florian ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; DRUG ANTIBODY; NEUTRALIZING ANTIBODY; NYOBLOC; TOXIN ANTIBODY; UNCLASSIFIED DRUG; MUSCLE RELAXANT AGENT;

ADOLESCENT; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CASE REPORT; CEREBRAL PALSY; CLASSIFICATION; CROSS REACTION; DRUG RESPONSE; DYSKINESIA; DYSPHAGIA; HUMAN; HYPERSALIVATION; LEARNING DISORDER; MALE; MOTOR PERFORMANCE; MULTIPLE CYCLE TREATMENT; PHAGOCYTE; PRIORITY JOURNAL; SALIVARY GLAND; UNSPECIFIED SIDE EFFECT; XEROSTOMIA; DRUG ADMINISTRATION; DRUG EFFECT; FOLLOW UP; HOSPITALIZATION; IMMUNOLOGY; MOTOR DYSFUNCTION; PATHOPHYSIOLOGY; RECURRENT DISEASE;

ADOLESCENT; ANTIBODY FORMATION; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; LEARNING DISORDERS; MALE; MOVEMENT DISORDERS; NEUROMUSCULAR AGENTS; RECURRENCE; SALIVARY GLANDS; SEVERITY OF ILLNESS INDEX; SIALORRHEA;

EID: 33847027359     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1017/S0012162207000151.x     Document Type: Article

References (12)

1. Tahmassebi JF, Curzon ME. (2003) Prevalence of drooling in children with cerebral palsy attending special schools. Dev Med Child Neurol 45: 613-617.
2. Jost WH. (1999) Treatment of drooling in Parkinson's disease with botulinum toxin. Mov Disord 14: 1057. (Letter)
3. Jongerius PH, van den Hoogen FJ, van Limbeek J, Gabreels FJ, van Hulst K, Rotteveel JJ. (2004) Effect of botulinum toxin in the treatment of drooling: A controlled clinical trial. Pediatrics 114: 620-627.
4. Savarese R, Diamond M, Elovic E, Millis SR. (2004) Intraparotid injection of botulinum toxin A as a treatment to control sialorrhea in children with cerebral palsy. Am J Phys Med Rehabil 83: 304-311.
5. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. (1997) Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 39: 214-223.
6. Thomas-Stonell N, Greenberg J. (1988) Three treatment approaches and clinical factors in the reduction of drooling. Dysphagia 3: 73-78.
7. Jankovic J, Vuong KD, Ahsan J. (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60: 1186-1188.
8. Dressler D, Bigalke H. (2005) Botulinum toxin type B de novo therapy of cervical dystonia: Frequency of antibody induced therapy failure. J Neurol 252: 904-907.
9. Dressler D, Benecke R. (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 49: 34-38.
10. BTX-B Adult Dosing Guidelines. (2006) http://www.mdvu.org/library/ dosingtables/btxb_adg.html; edition 1.0. (Accessed July 2006).
11. Ondo WG, Hunter C, Moore W. (2004) A double-blind placebocontrolled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 62: 37-40.
12. Sesardic D, Jones RG, Leung T, Alsop T, Tierney R. (2004) Detection of antibodies against botulinum toxins. Mov Disord 19 (Suppl. 8): S85-91.